Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
IRVING, Texas and ABBOTT PARK, Ill., Nov. 20, 2010 /PRNewswire-FirstCall/ — Reata Pharmaceuticals and Abbott (NYSE: ABT) today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the …
Read more on redOrbit
New I-SPY 2 study to evaluate effectiveness of medical treatment for breast cancer
A clinical trial that aims to speed up the study of new treatments for certain subtypes of breast cancer now has a designated study site at the Diane O’Connor Thompson Breast Center at the University of Colorado Hospital.
Read more on News-Medical-Net
Water treatment facility seen to boost business
GENERAL SANTOS CITY — The Department of Environment and Natural Resources (DENR) has accredited a water testing and waste water treatment laboratory facility in nearby Sarangani, a move seen to help the local business sector, officials said.
Read more on Sun Star